**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**FILING UNDER 37 C.F.R. 1.53(b)** 

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This is a request for filing a patent application under 37 CFR 1.53(b).

| INVENTOR(S)       |                     |                        |
|-------------------|---------------------|------------------------|
| First Name        | Middle Name         | Family Name or Surname |
| 1. Hiroaki        | 1.                  | 1. Udagawa             |
| 2. Torben         | 2. Peter            | 2. Frandsen            |
| 3. Tom            | 3. Anton Busk       | 3. Nielsen             |
| 4. Markus         | 4. Sakari           | 4. Kauppinen           |
| 5. Soren          | 5.                  | 5. Christensen         |
|                   | TITLE OF THE INVENT |                        |
| Lysophospholipase |                     |                        |

The following application parts are enclosed:

[x] specification

26 pages

[x] Sequence Listing 30 pages

[x] Abstract

1 page

[] Formal Drawings pages

The filing fee is calculated as follows:

Basic Fee:

\$770.00

Total Claims:  $15 - 20 = 0 \times 18 =$ 

\$0.00

Independent Claims:  $1 - 3 = 0 \times 88 =$ 

\$0.00

Total Fee:

\$770.00

Priority of Danish application no. PA 1999 01473 filed on October 14, 1999 is claimed under 35 U.S.C. 119(a)-(d). A certified copy is submitted herewith.

The benefit of U.S. provisional application no. 60/160,572 filed on October 20, 1999 is claimed under 35 U.S.C. 119(e).

The benefit of U.S. application no. 10/309,437, filed December 4, 2002, no. 09/687,538 filed on October 13, 2000, and application no. 09/678,513 filed on October 3, 2000 is claimed under 35 U.S.C. 120.

An application data sheet is enclosed.

This application contains a Sequence Listing. The computer-readable form in this application is identical with that filed in application no. 09/687,538 filed October 13, 2000. In



accordance with 37 CFR 1.821(e), please use the computer readable form filed in that application as the computer readable form for the instant application.

The assignee of the present application is:

Novozymes A/S Krogshoejvej 36 DK-2880 Bagsvaerd Denmark

Applicants request that the assignee information be included in the published patent application.

Direct all correspondence to Customer Number 25908:

Please charge the required fee, estimated to be \$770, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: May 19, 2004

Jason I. Garbell, Reg. No. 44,116 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110

(212) 840-0097

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## **EXPRESS MAIL CERTIFICATE**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Patent Application for

Lysophospholipase

Applicants: Udagawa et al.

Sir:

Express Mail Label No. EL 988468550 US

Date of Deposit: May 19, 2004

I hereby certify that the following attached paper(s) or fee

- 1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
- 2. Patent Application
- 3. Application Data Sheet
- 4. Preliminary Amendment
- 5. Sequence Listing
- 6. Information Disclosure Statement
- 7. Form PTO/SB/08A
- 8. Executed Declaration

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and to the address indicated above.

Julie Tabarovsky

(Name of person mailing paper(s) or fee)

\$ignature of person malling paper(s) or fee)

Mailing Address: Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110 (212) 840-0097